张鹏， 生物化学与分子生物学博士，副教授，硕士研究生导师，张鹏课题组聚焦天然毒液来源抗癌/抗菌活性多肽筛选、优化改造及作用分子机制研究，筛选鉴定了JZ-66(66个氨基酸残基)、SVHAO(398个氨基酸残基)等多个序列新颖抗癌肽；系统性解析狼蛛毒素多肽Lycosin-I的多模式抗癌作用机制，尤其是其诱导癌细胞发生铁死亡机制，极大的丰富了抗癌肽作用机制理论[2]；以Lycosin-I为模板，设计改造出pHly-I[3]、Ly-Glc(8a)[5] 和Ly(PEG)-1等多个极具抗癌/抗菌药物开发前景的改造体；拓展多肽自组装特性及应用，设计开发癌细胞高表达硫酸酯酶[1]和免疫微环境[4]响应的可控组装体系，系列成果以通讯作者和第一作者在J.Am.Chem.Soc、Adv.Sci、Theranostics、Nano.Res、J.Med.Chem(×3)等杂志上发表论文15篇；申请国家发明专利8项，授权4项，获湖南省十大颠覆性创新技术奖，获“红枫计划”多肽产品研发投资 50 万元。主持国家自然科学基金委面上、青年基金等国家、省部级项目 8 项，入选首届湖南省优秀博士后创新人才。指导本科生获全国大学生生命科学竞赛二等奖 2 项、三等奖 1 项，获省级创新创业项目 2 项，获各类大学生创新创业大赛奖励 5 项。
Zhang Peng, Ph.D., Associate Professor and Master's Supervisor in Biochemistry and Molecular Biology, leads a research group specializing in the screening, optimization, and molecular mechanism investigation of anticancer and antibacterial peptides derived from natural venoms. His group has identified multiple novel anticancer peptides, including JZ-66 (66 amino acid residues) and SVHAO (398 amino acid residues), and systematically elucidated the multimodal anticancer mechanisms of the wolf spider toxin peptide Lycosin-I, particularly its role in inducing ferroptosis in cancer cells, significantly advancing the theoretical understanding of anticancer peptide mechanisms[2]. Using Lycosin-I as a template, his group has designed several optimized peptide analogs, including pHly-I[3], Ly-Glc(8a)[5], and Ly(PEG)-1, and developed controllable peptide assembly systems responsive to sulfatase overexpression[1] in cancer cells and the tumor immune microenvironment[4] . Dr. Zhang has published 15 papers as corresponding author or first author in high-impact journals including J. Am. Chem. Soc., Adv. Sci., Theranostics, Nano Res., and J. Med. Chem. (3 publications), and holds 5 granted patents in China. These achievements have been recognized with Hunan Province's Top Ten Disruptive Innovation Technologies award and secured 500,000 yuan in R&D investment through the "Red Maple Program."
代表性研究成果(Representative Research Achievements)：
[1] Chen N, Zhang Z, Liu X, Wang H, Guo RC, Wang H, Hu B, Shi Y*, Zhang P*, Liu Z, Yu Z*. Sulfatase-Induced In Situ Formulation of Antineoplastic Supra-PROTACs. J Am Chem Soc. 2024;146(15):10753-10766.
[2] Zhang P, Luo W*, Zhang Z, Lv M, Sang L, Wen Y, Wang L, Ding C, Wu K, Li F, Nie Y, Zhu J, Liu X, Yi Y*, Ding X*, Zeng Y, Liu Z*. A Lipid-Sensitive Spider Peptide Toxin Exhibits Selective Anti-Leukemia Efficacy through Multimodal Mechanisms. Adv Sci (Weinh). 2024;11(32):e2404937.
[3] Zhang P*, Wu S, Li J, Bu X, Dong X, Chen N, Li F, Zhu J, Sang L, Zeng Y, Liang S, Yu Z*, Liu Z*.Dual-sensitive antibacterial peptide nanoparticles prevent dental caries. Theranostics. 2022 Jun 13;12(10):4818-4833.
[4] Zhang Z, Liu J, Xiao M, Zhang Q, Liu Z, Liu M*, Zhang P*, Zeng Y*. Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma. Nano Res. 2023;16(4):5206-5215.
[5] Zhang P, Ma J, Zhang Q, Jian S, Sun X, Liu B, Nie L, Liu M, Liang S, Zeng Y*, Liu Z*. Monosaccharide Analogues of Anticancer Peptide R-Lycosin-I: Role of Monosaccharide Conjugation in Complexation and the Potential of Lung Cancer Targeting and Therapy. J Med Chem. 2019;62(17):7857-7873.